0.00Open0.45Pre Close0 Volume16 Open Interest2.50Strike Price0.00Turnover152.24%IV2.15%PremiumDec 20, 2024Expiry Date0.41Intrinsic Value100Multiplier4DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.8651Delta0.6612Gamma4.66Leverage Ratio-0.0084Theta-0.0002Rho-4.03Eff Leverage0.0005Vega
Sutro Biopharma Stock Discussion
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer
Tuesday, 10th December at 8:00 am
- 32% objective response rate (ORR) in evaluable patients at the 5.2 mg/kg starting dose – the selected dose for randomized portion (Part 2) of ongoing registrational REFRαME-O1 trial -
- These data confirm luvelta's robust response rate in patients with late-stage ovarian c...
Sutro Biopharma Announces Initiation of the Registration-Enabling RefrΑMe-P1 Trial With Luvelta for Pediatric Patients With Cbf/Glis Aml
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML
Sutro Biopharma has initiated REFRαME-P1, a registration-enabling trial of luveltamab tazevibulin (luvelta) for pediatric patients with CBF/GLIS AML. The study follows encouraging compassionate use data presented in December 2023, showing 42% complete remission in patients with ≥5% blasts. CBF/GLIS AML is a rare, aggressive leuke...
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum
Sutro Biopharma (NASDAQ: STRO) is hosting an investor webcast to showcase its proprietary cell-free platform and next-generation ADC innovation. The company highlights three approaches: increasing potency safely with higher drug-antibody ratio exatecan ADCs, combining payloads to overcome tumor resistance with dual-payload ADCs (ADC2), and delivering immunostimulatory...
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024
Sutro Biopharma (NASDAQ: STRO) announced updated data from its Phase 1b study of luveltamab tazevibulin (luvelta) in combination with bevacizumab for epithelial ovarian cancer (EOC) at ESMO 2024. Key findings include:
- 56% objective response rate at the recommended phase 2 dose (RP2D) of 4.3 mg/kg luvelta with 15 mg/kg bevacizumab
- 35% overal...
Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer
Sutro Biopharma (NASDAQ: STRO) has initiated the REFRαME-L1 global Phase 2 study of luveltamab tazevibulin (luvelta) for non-small cell lung cancer (NSCLC)patients with Folate Receptor-α (FRα) expressing tumors.
The trial is now open for enrollment, with initial data expected in H1 2025. Luvelta, an antibody drug conjugate (ADC), shows promise...
Sutro Biopharma Announces Initiation of RefrΑMe-L1 Phase 2 Trial With Luvelta for Patients With Non-Small Cell Lung Cancer
Title: Luveltamab tazevibulin, an antifolate receptor alpha (FRα) antibody-drug conjugate (ADC), in combination with bevacizumab (b...
Dow Jones· 2 mins ago
No comment yet